ArticleDigestive diseases and sciences2025
Clinical, Radiological and Pharmacokinetic Data of CT-P13 Subcutaneous in Individuals with Fistulizing Anoperineal Crohn's Disease.
Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Subcutaneous infliximab in the treatment of patients with perianal fistulizing Crohn's disease: current evidence and emerging roles.Therapeutic advances in gastroenterology · 2026Review
- Comment on "Clinical, Radiological and Pharmacokinetic Data of CT‑P13 Subcutaneous in Individuals with Fistulizing Anoperineal Crohn's Disease".Digestive diseases and sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeThe aim of this study was to evaluate the clinico-radiological remission rate in patients with fistulizing anoperineal lesions of Crohn's disease treated with CT-P13 SC, as well as pharmacokinetic data and treatment persistence rate.
methodsWe included all consecutive patients seen in the dedicated proctology outpatient clinic between June 1st and July 15th, 2024, for fistulizing anoperineal lesions and treated for at least 3 months with CT-P13 SC. Clinical, radiological and pharmacokinetic data were collected.
resultsData from 39 patients were analyzed. The median duration of treatment was 16.1 months. Seventeen patients (43.6%) had initiated SC formulation upfront. The complete clinical remission rate was 74.4%, significantly higher in patients switched from IV to SC formulation. Among patients switched from IV to SC formulation, 86.5% maintained remission. In the overall study population, 89.7% were able to continue treatment, with intensified protocols in 61.5% of patients. The deep radiological remission rate was 61.5%. The median infliximab concentration was 22.7 µg/mL. Only the intensified administration protocol was significantly associated with higher infliximab concentrations. Immunosuppressants had no impact. The median infliximab concentration was higher in patients in remission (35.9 µg/mL vs 22.4 µg/mL), but without any significant difference.
conclusionCT-P13 SC appears to be at least as effective as the IV formulation for fistulizing anoperineal lesions, and switching from IV to SC allows remission to be maintained in the vast majority of cases. Despite numerically higher infliximab concentrations in patients in remission, no significant difference could be identified. Trial registration number and date: Registration with the ethics committee on 11/14/2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.